Author

Mark A. Vanden Avond

Observed names: Mark A Vanden Avond, Mark Mark Vanden Avond, Mark Vanden Avond, Vanden Avond, Mark
ORCID: 0000-0003-4872-1993
Observed ORCID: 0000-0003-4872-1993
OpenAlex ID: A5002575942
2021 · Shelby E. Hamm, Daniel D. Fathalikhani, et al. · Molecular Therapy — Methods & Clinical Development · 26
2020 · Mark A. Vanden Avond, Hui Meng, et al. · Journal of Inherited Metabolic Disease · 11
2023 · Jennifer A. Tinklenberg, Rebecca A. Slick, et al. · American Journal Of Pathology · 9
2019 · Daniel C Helbling, David Mendoza, et al. · Journal of Neuropathology & Experimental Neurology · 8
2025 · Hong Xue, Manoj K. Mishra, et al. · Cell Reports · 7
2026 · Qiongzi Qiu, Yong Liu, et al. · Science · 4
2021 · Shelby E. Hamm, Daniel D. Fathalikhani, et al. · Molecular Therapy — Methods & Clinical Development · 1
2026 · Mark Vanden Avond, Michael N. Grzybowski, et al. · Physiological Genomics
2025 · Justine Abais-Battad, Mark Vanden Avond, et al. · Physiology
2019 · Jennifer Tinklenberg, Rebecca A. Slick, et al. · UWA Profiles and Research Repository (UWA)
2014 · Carlee Toddes, Molly A. Barlow, et al. · Minds at UW (University of Wisconsin)
2013 · Amy Johnson, Krystal A. Reed, et al. · Minds at UW (University of Wisconsin)
2013 · Mark A. Vanden Avond, Amy R. Johnson, et al. · The FASEB Journal
Works count: 20
Citation count: 94
H-index: 7
I10-index: 3
Year
Topic
Type